# Depletion of Serum Amyloid P Component to Enhance the Immune Response to DNA Vaccination

> **NCT02425241** · PHASE1,PHASE2 · COMPLETED · sponsor: **University College, London** · enrollment: 41 (actual)

## Conditions studied

- HIV

## Interventions

- **BIOLOGICAL:** pSG2.HIVconsv DNA vaccine
- **BIOLOGICAL:** ChAdV63.HIVconsv booster vaccine
- **BIOLOGICAL:** MVA.HIVconsv booster vaccine
- **DRUG:** CPHPC
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02425241
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2016-02
- **Final completion:** 2016-09
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2020-03-26

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02425241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02425241, "Depletion of Serum Amyloid P Component to Enhance the Immune Response to DNA Vaccination". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02425241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*